Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) Meeting Abstract
| Authors: | Dileo, P.; Rankin, C. J.; Benjamin, R. S.; von Mehren, M.; Blanke, C.; Bramwell, V.; Maki, R.; Fletcher, C.; Borden, E. C.; Demetri, G. D. |
| Abstract Title: | Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) |
| Meeting Title: | 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2005 May 13-17 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-06-01 |
| Start Page: | 824S |
| Language: | English |
| ACCESSION: | WOS:000230326605335 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2005.23.16_suppl.9009 |
| Notes: | --- - Meeting Abstract: 9032 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos" |
